Claudio Laudani Compares Aspirin and P2Y12 Inhibitor Monotherapy in ACS Patients After PCI
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
“Aspirin: another nail in the coffin? (For ACS)
In this systematic review and meta-analysis, we compared the relative benefits of aspirin and P2Y12 inhibitor monotherapy after a short DAPT in ACS patients undergoing PCI.
At interaction analysis, the benefits of short DAPT compared to standard DAPT appear to be driven by P2Y12 inhibitor monotherapy, rather than aspirin monotherapy.
Indeed, P2Y12 inhibitor monotherapy reduced NACE, any bleeding and major bleeding, while aspirin monotherapy retrieved neutral results.
At indirect comparison through network meta-analysis, P2Y12 inhibitor monotherapy reduced NACE by 23% and any bleeding by 32% compared to aspirin monotherapy.
Finally, more robust and high quality evidence exist for P2Y12 inhibitor monotherapy, especially ticagrelor, and our trial sequential analysis reflected this result.”
Read the full article here.
Article: Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Authors: Claudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, Mattia Galli, Antonio Greco, Marco Spagnolo, Luis Ortega-Paz, Francesco Costa, Dominick J. Angiolillo, Davide Capodanno
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology